Company intelligence / Profile preview

RespiRelax+

Glen Rock, New Jersey, USAplay.google.com ↗

Ownership: Private
Development stage: Commercial

Overview

RespireRx’s lead candidate CX1739 has completed multiple Phase 1 safety trials and Phase 2 proof-of-concept studies demonstrating target engagement. A Department of Defense grant is funding a two-stage Phase 2A/2B study in spinal cord injury patients to assess improvement in bladder function and motor activity. The company also develops dronabinol for obstructive sleep apnea, with plans for a new formulation and subsequent pharmacokinetic and Phase 3 studies pending FDA discussions.

Therapeutic areas: PulmonologyPsychiatryNeurology
Modalities: Small moleculeSynthetic cannabinoid
Industry: Biotech

Partnerships

Shirley Ryan AbilityLabUniversity of Florida research collaborationUWM Research Foundation option/license agreement

Beyond the preview

Go deeper on RespiRelax+.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RespiRelax+.

Explore the full profile